Laboratoires (ALEMG) | Financial Analysis & Statements
Laboratoires Euromedis S.A. | Small-cap | Healthcare
Laboratoires Euromedis S.A. | Small-cap | Healthcare
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
36.2M
Gross Profit
1.9M
5.32%
Operating Income
1.3M
3.62%
Net Income
-6.1M
-16.87%
Balance Sheet Metrics
Total Assets
38.8M
Total Liabilities
22.3M
Shareholders Equity
16.5M
Debt to Equity
1.35
Cash Flow Metrics
Operating Cash Flow
-5.9M
Free Cash Flow
-2.1M
Revenue & Profitability Trend
Laboratoires Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 36.2M | 34.0M | 54.2M | 111.9M | 193.4M |
| Cost of Goods Sold | 34.3M | 33.9M | 35.4M | 78.4M | 129.3M |
| Gross Profit | 1.9M | 181.7K | 18.7M | 33.5M | 64.2M |
| Operating Expenses | 1.2M | 3.2M | 19.6M | 41.0M | 41.2M |
| Operating Income | 1.3M | -4.3M | -5.4M | 3.7M | 28.7M |
| Pre-tax Income | 376.7K | 21.7M | -6.0M | 2.5M | 28.5M |
| Income Tax | -3.9K | 269.0K | -41.0K | 210.0K | 5.5M |
| Net Income | -6.1M | 13.1M | -5.9M | 2.3M | 22.9M |
| EPS (Diluted) | - | €4.60 | -€1.97 | €0.63 | €6.33 |
Income Statement Trend
Laboratoires Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 37.6M | 39.3M | 51.9M | 64.4M | 83.3M |
| Non-Current Assets | 1.1M | 7.0M | 8.0M | 8.3M | 9.3M |
| Total Assets | 38.8M | 46.3M | 59.9M | 72.7M | 92.6M |
| Liabilities | |||||
| Current Liabilities | 10.7M | 8.9M | 9.5M | 13.7M | 34.1M |
| Non-Current Liabilities | 11.6M | 14.8M | 15.4M | 17.8M | 19.6M |
| Total Liabilities | 22.3M | 23.7M | 25.0M | 31.5M | 53.7M |
| Equity | |||||
| Total Shareholders Equity | 16.5M | 22.6M | 34.9M | 41.2M | 38.9M |
Balance Sheet Composition
Laboratoires Cash Flow Statement From 2017 to 2022
| Metric | 2022 | 2021 | 2020 | 2019 | 2017 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -5.9M | 2.3M | 22.9M | -3.6M | -134.0K |
| Operating Cash Flow | -5.9M | 2.4M | 22.9M | -2.7M | -1.1M |
| Investing Activities | |||||
| Capital Expenditures | -1.0M | -1.4M | -653.0K | -1.4M | 8.0K |
| Investing Cash Flow | -1.1M | -1.1M | -592.0K | -1.2M | -734.0K |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | -269.0K |
| Financing Cash Flow | -2.1M | -1.3M | 9.4M | 3.4M | -52.0K |
| Free Cash Flow | -2.1M | 17.4M | 12.8M | -2.3M | -232.0K |
Cash Flow Trend
Laboratoires Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
28.13
Forward P/E
10.55
Price to Book
0.73
Price to Sales
0.33
PEG Ratio
10.55
Profitability Ratios
Profit Margin
-16.78%
Operating Margin
5.27%
Return on Equity
-31.26%
Return on Assets
0.58%
Financial Health
Current Ratio
2.97
Debt to Equity
48.76
Beta
0.28
Per Share Data
EPS (TTM)
€0.15
Book Value per Share
€5.80
Revenue per Share
€12.64
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| alemg | 12.0M | 28.13 | 0.73 | -31.26% | -16.78% | 48.76 |
| Bastide le Confort | 223.2M | 26.34 | 2.98 | 10.46% | 0.32% | 541.81 |
| Metrics In Balance | 790.3K | - | 0.01 | -0.45% | -17,317.00% | - |
| bioMérieux S.A | 14.2B | 32.96 | 3.37 | 10.68% | 10.86% | 11.65 |
| Eurofins Scientific | 10.6B | 28.48 | 2.56 | 7.71% | 5.85% | 67.05 |
| Ipsen S.A | 8.4B | 23.61 | 1.99 | 8.93% | 9.68% | 12.33 |
Financial data is updated regularly. All figures are in the company's reporting currency.